Study: Sodium hyaluronate solution safe, effective
September 1st 2009An investigational compound for the treatment of dry eye disease consisting of a proprietary formulation of sodium hyaluronate ophthalmic solution 0.18% (Vismed, Lantibio Inc.) was shown to be safe and effective in a multicenter phase III trial conducted in the United States. A new drug application has been filed for the solution, which is already marketed in parts of Europe and Asia as a viscoelastic lubricant eye drop.
Don't go postal, go dental: remain aloof to organized medicine
September 1st 2009While ophthalmology has traveled down the road harnessed to organized medicine and thereby exposed to all of the exploding impediments to practice, dentistry has alertly remained aloof to these changes and continues to be viable, productive, and secure.
Vision care is lacking for children today
September 1st 2009Healthy vision is vital for success in life and should begin with regular vision screenings during childhood, but the level of inadequate vision care for children in the United States is significant, however. The author addresses ways to address this issue to positively affect high school graduation rates, social and emotional problems, juvenile delinquency, adult literacy problems, incarcerations, and workforce quality and productivity.
Glaucoma minishunt under scleral flap demonstrates long-term efficacy and safety
September 1st 2009A retrospective study analyzed outcomes of 345 consecutive eyes with the proprietary glaucoma minishunt (Ex-PRESS, Optonol) implanted, including 114 eyes having combined cataract surgery. During a mean follow-up of about 2 years, the implant provided effective IOP control whether used alone or in a combination procedure and was associated with few complications.
Preservative-free IOP-lowering medications of interest to ophthalmologists, survey finds
September 1st 2009Results of a survey of 124 ophthalmologists show interest in preservative-free formulations of IOP-lowering medications to preserve ocular surface health. Preservative-free timolol maleate (Timoptic in Ocudose, Aton Pharma) can be a good choice for appropriately selected patients, according to one ophthalmologist.
Glaucoma: Trabecular micro-bypass device aids IOP reduction in prospective study
September 1st 2009Implantation of a trabecular micro-bypass (iStent, Glaukos Corp.) in patients with open-angle glaucoma who are undergoing cataract surgery represents an alternative surgical approach that can provide clinically significant reductions in IOP and use of ocular hypotensive medications.
Endocyclophotocoagulation beneficial for those with glaucoma undergoing cataract surgery
September 1st 2009Endocyclophotocoagulation (ECP) can be performed easily in patients with medically controlled glaucoma who are undergoing cataract surgery, to provide additional IOP lowering and reduce medication use. Misunderstanding that ECP is a completely different procedure than transscleral cyclodestruction contributes to under-use of this very safe procedure, according to one ophthalmologist.
Glaucoma: Hyperemia a common cause for medication changes
September 1st 2009Hyperemia is one of the main reasons why patients with glaucoma do not adhere to or persist with their topical therapeutic regimen. Patients end up switching to another possibly more tolerable medication, and the changing of medications has significant financial implications. Latanoprost has the lowest incidence of hyperemia among the prostaglandin analogs. Patient adherence is crucial in a chronic progressive disease such as glaucoma, where non-adherence can lead to visual loss and decline in quality of life, creating societal health and economic burdens.
Prostaglandin analogue monotherapy's long duration may be associated with lower costs
September 1st 2009Longer duration of use of monotherapy with prostaglandin analogues may be associated with lower annual costs of glaucoma treatment because adjunctive therapy is one of the primary factors affecting the cost of care, suggest findings of a retrospective analysis of a pharmacy claims database.
Glaucoma: Bimatoprost tolerability appears to be enhanced with switching strategy
September 1st 2009The efficacy and tolerability of continuing latanoprost 0.005% (Xalatan, Pfizer) after 6 weeks of latanoprost monotherapy versus switching to bimatoprost 0.03% (Lumigan, Allergan) was investigated in an investigator-masked, randomized, parallel-group trial. The results showed good efficacy and tolerability in patients whose therapy was switched to bimatoprost and suggest that bimatoprost may be tolerated better after latanoprost pre-treatment.
Canaloplasty may be alternative to trabeculectomy
September 1st 2009Non-penetrating Schlemm's canaloplasty may be a safe and effective alternative to standard trabeculectomy. A retrospective comparison study found no statistically significant differences in IOP reduction or medication usage at up to 1 year of follow-up. Adjunctive procedures and complications were similar in the two groups of patients, although no long-term hypotony was seen in the canaloplasty group.
Bausch & Lomb opens new pharma headquarters
September 1st 2009Bausch & Lomb has opened a new 300,000-square-foot global pharmaceutical headquarters building in Madison, NJ. The company maintains its worldwide headquarters in Rochester, NY, and has research and development functions in locations around the world.
National Correct Coding Initiative enables better reporting of multiple services
September 1st 2009It is imperative, especially in uncertain economic times, for physicians to be thoroughly familiar with Medicare's National Correct Coding Initiative (NCCI). This initiative was put forth in 1996 in order to promote correct coding and to serve as a ready mechanism by which to reduce improper coding.
Microincisional IOL debuts for cataract surgery
September 1st 2009The first microincisional IOL (Akreos MICS IOL, Bausch & Lomb) has been introduced in the U.S. market. The lens is a single-piece hydrophilic acrylic IOL designed for delivery through a 1.8-mm incision. Its material and design offer several advantages, according to three surgeons who have used it.
Glaucoma: Latest brimonidine formulation shows improved safety, tolerability
September 1st 2009A meta-analysis based on data from 12-month trials including patients treated with brimonidine 0.1% with a preservative (Alphagan P 0.1% with Purite, Allergan) and patients using brimonidine 0.15% (Alphagan P 0.15%, Allergan) showed better systemic safety and tolerability with the lower-concentration product.
Brimonidine/timolol controls IOP in clinical setting
September 1st 2009Brimonidine 0.2%/timolol 0.5% fixed-combination ophthalmic solution effectively lowers and controls IOP and is likely to be associated with increased patient adherence to therapy and decreased unwanted side effects such as ocular irritation, according to one ophthalmologist.
Lowering levels of arginase may halt progression of diabetic retinopathy
August 24th 2009High levels of the enzyme arginase contributes to vascular eye damage, and therapies to lower its levels could halt progression of diabetic retinopathy, according to researchers at the Medical College of Georgia (MCG) School of Medicine.
NicOx and Pfizer sign agreement for PF-03187207
August 19th 2009NicOx has signed an agreement with Pfizer to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open-angle glaucoma and ocular hypertension, according to a prepared statement.
Research shows children would benefit from comprehensive eye exams
August 19th 2009A new report from the National Commission on Vision and Health concludes that even though universal comprehensive eye exams for children conducted prior to starting school would result in more vision problems and eye diseases being diagnosed and treated successfully in children, requirements vary widely from state to state, and only three states require eye examinations for school-aged children.